Ticker Hub
BMY — AI Analysis & Sentiment
9 recent AI-generated analyses for BMY. Sentiment and confidence insights updated continuously.
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibb's Camzyos sNDA acceptance for priority review for adolescents with oHCM presents a strong growth opportunity. The market has y...
Jun 1, 2026Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb's positive Phase 3 results for Mezigdomide in multiple myeloma present a significant long-term growth opportunity, with the dr...
May 29, 2026Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
Bristol Myers Squibb's expanded AI collaboration with Tempus positions the company for improved R&D efficiency and higher clinical trial success ra...
May 14, 2026Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
EC approval for Sotyktu in active psoriatic arthritis expands the market opportunity for BMY. Despite a negative market reaction, this strengthens ...
May 8, 2026Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
Bristol Myers Squibb's partnership to distribute Eliquis through Cost Plus Drugs should expand market access and potentially boost long-term sales,...
Apr 24, 2026Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Bristol Myers Squibb announced strong new data for Camzyos, reinforcing its leadership in oHCM and showing potential for a new adolescent indicatio...
Mar 23, 2026Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
The expanded FDA and EMA approvals for Opdivo significantly broaden its market for Classical Hodgkin Lymphoma patients, enhancing Bristol Myers Squ...
Mar 20, 2026U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Bristol Myers Squibb received FDA approval for Sotyktu to treat active psoriatic arthritis, a significant expansion for its drug portfolio. This fi...
Mar 7, 2026SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Positive Phase III clinical trial results for iza-bren significantly strengthen Bristol Myers Squibb's long-term oncology pipeline and revenue pote...
Feb 28, 2026